TKT

Transketolase · P29401 · TKT on Sugi Atlas →

2,846 patent compounds predicted against TKT, 1,894 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Hydrochloric Acid (SCHEMBL1267295)	0.98	20/20
Hydrochloric Acid (SCHEMBL4095927)	0.98	20/20
Hydrochloric Acid (SCHEMBL4090733)	0.80	20/20
SCHEMBL4881064	0.50	20/20
SCHEMBL1267299	1.00	19/20
SCHEMBL1267303	1.00	19/20
Hydrochloric Acid (SCHEMBL1267202)	1.00	17/20
SCHEMBL4881061	1.00	17/20
Hydrochloric Acid (SCHEMBL1266260)	0.98	17/20
Hydrochloric Acid (SCHEMBL1267294)	0.98	17/20
Hydrochloric Acid (SCHEMBL4102447)	0.98	17/20
Hydrochloric Acid (SCHEMBL4100634)	0.95	17/20
Hydrochloric Acid (SCHEMBL648277)	0.70	17/20
Hydrochloric Acid (SCHEMBL1267212)	0.64	17/20
SCHEMBL6936412	0.56	17/20
Hydrochloric Acid (SCHEMBL244785)	0.55	17/20
Bromide (SCHEMBL3854523)	0.55	17/20
Hydrochloric Acid (SCHEMBL1491223)	0.54	17/20
SCHEMBL1267628	1.00	16/20
SCHEMBL1266273	0.89	16/20

Clinical trials — most relevant to TKT by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Prevention of Renal Complications of Diabetes With Thiamine	PHASE4	UNKNOWN
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)	PHASE3	WITHDRAWN
Targeting de Novo Pyrimidine Biosynthesis by Leflunomide for the Treatment of COVID-19 Virus Disease	PHASE3	COMPLETED
To Assess Safety of Mitapivat and Provide Proof of Concept of the Efficacy of the Drug in Patients With RBC Membranopathies or CDAII.	PHASE2	RECRUITING
A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung	PHASE2	COMPLETED
Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer	PHASE2	UNKNOWN
Treatment of TK2 Deficiency With Thymidine and Deoxycytidine	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis	PHASE2	COMPLETED
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer	PHASE1/PHASE2	RECRUITING
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma	PHASE1	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
A Retrospective Study of Subjects With Thymidine Kinase 2 Deficiency	nan	COMPLETED
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy	nan	UNKNOWN
Thiamine As An Adjuvant Therapy For Hyperlactatemia In Septic Shock Patients	nan	UNKNOWN
Pyruvate Kinase Deficiency Epidemiological Study (PIECE)	nan	COMPLETED
Pyruvate Kinase Deficiency Global Longitudinal Registry	nan	ACTIVE_NOT_RECRUITING
Proof of Concept Creatine Supplementation for Homocystinuria Study	nan	ACTIVE_NOT_RECRUITING
Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)	nan	RECRUITING
Systemic Inflammatory Response: Thiamine and Magnesium Status (Sir TaM Study)	nan	COMPLETED
13C Pyruvate DNP MR Spectroscopy for Lymphoma Treatment Response Assessment	nan	UNKNOWN
Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC	nan	UNKNOWN
The Role of Sugars in Fat Accumulation in the Liver	nan	RECRUITING
Biomarkers in Exhaled Breath Condensates in Acute Lung Injury: Early Detection and Outcome Predictors	nan	UNKNOWN
Maternal Inborn Errors of Metabolism in Pregnancy: A Pregnancy Registry Protocol	nan	COMPLETED
McArdle Disease Treatment by Ketogenic Diet	nan	COMPLETED
Polycystic Ovary Syndrome in Type 1 Diabetes	nan	NOT_YET_RECRUITING
Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease	nan	RECRUITING
Pyruvate Kinase Deficiency Natural History Study	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TKT binder may also engage these)

Protein	Name	Similarity
Q6B855	—	1.000	Q6B855 →
Q5R1W6	—	1.000	Q5R1W6 →
Q60HC7	—	1.000	Q60HC7 →
Q5R4C1	—	1.000	Q5R4C1 →
P40142	—	1.000	P40142 →
P50137	—	1.000	P50137 →
Q9D4D4	—	0.988	Q9D4D4 →
Q2NKZ4	—	0.970	Q2NKZ4 →
Q9H0I9	—	0.953	Q9H0I9 →
Q2NL26	—	0.951	Q2NL26 →
CTH	Cystathionine gamma-lyase	0.949	landscape →
P27819	—	0.949	P27819 →
Q60HG7	—	0.948	Q60HG7 →
P09342	—	0.948	P09342 →
P27818	—	0.945	P27818 →
Q9SUW2	—	0.943	Q9SUW2 →
P09114	—	0.941	P09114 →
Q41768	—	0.940	Q41768 →
P17764	—	0.938	P17764 →
P17597	—	0.938	P17597 →
OAT	Ornithine aminotransferase, mitochondrial	0.938	landscape →
Q5BKN8	—	0.937	Q5BKN8 →
Q41769	—	0.937	Q41769 →
P24226	—	0.937	P24226 →
Q43199	—	0.937	Q43199 →
Q9H2P9	—	0.936	Q9H2P9 →
P36871	—	0.936	P36871 →
A3QK15	—	0.936	A3QK15 →
Q8QZT1	—	0.936	Q8QZT1 →
Q6K2E8	—	0.936	Q6K2E8 →